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Post-TACEAbstract Objective: To evaluate role of DWI in assessment of H.C.C. after TACE.
Patients and methods: Twenty patients with H.C.C., mainly in sixth and seventh decades under-
went TACE therapy. The baseline hepatic MRI before chemoembolization used 1.5-T closed mag-
net and then follow-up 3 weeks post-TACE included axial T1, T2 WI, DWI and dynamic contrast
study. DWI used b values 0, 300, and 600 s/mm2 then measured ADC value on dedicated worksta-
tion.
Results: ADC measurement within H.C.C. tumor was significantly lower than normal liver par-
enchyma before TACE with increased ADC in the necrotic tissue after TACE. Fifteen patients
showed a partial response with increased tumor necrosis. Complete response occurred in five
patients as absent residual viable tumor tissue on DWI. Statistical analysis showed that DWI has
sensitivity of 86.67%, specificity of 80%, positive predictive value of 92.86% and negative predictive
value of 66.67%.
Conclusions: MRI DWI offers quick and non-invasive technique to distinct between viable and
necrotic tumor areas and helps the diagnosis of residual tumor. Potential effect of treatment can
be detected as increase in the diffusion coefficient. We recommend that optimal follow-up after
image guided trans-catheter tumor therapy should include DWI and contrast-enhanced MRI.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is the commonest hepatic
malignancy. In Egypt, between 1993 and 2009, there was an
almost two and half fold increase in HCC among chronic liverpatients. With the highest prevalence of hepatitis C worldwide,
increasing urbanization, smoking rates, environmental expo-
sures, and aging, HCC will continue to rise in next few decades
forming major health problem (1,2).
HCC is an aggressive tumor with a median survival follow-
ing diagnosis of approximately 6–20 months. Surgical resec-
tion is considered to be the only curative treatment for
HCC, and but only a small number of patients were able to
undergo such treatment (3).
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apeutic and embolic agents has been used for almost 20 years.
Trans-arterial chemoembolization causes acute ischemic dam-
age to HCC and results in coagulative necrosis because HCC is
nourished only by the hepatic artery. Prior studies have shown
survival benefits of trans-arterial chemoembolization (TACE),
with cumulative survival probability superior to that achieved
with the best systemic chemotherapy (4).
Viable neoplastic tissue may remain in some cases after
TACE, so assessment of post-TACE tumor response is impor-
tant in determining treatment success and in guiding future
therapy. Early identification of treatment failure is also critical
in patient management, since a repeat treatment cycle can be
performed if liver function is maintained. The decision to
repeat TACE or look for alternative treatment should be based
on the assessment of residual tumor (5).
Follow-up using sonography, computed tomography and
magnetic resonance imaging has been used to assess therapeu-
tic efficacy. However, conventional imaging necessitates injec-
tion of contrast material and shows some limitations in the
evaluation of therapeutic efficacy (6).
Diffusion-weighted imaging (DWI), a functional MRI tech-
nique that detects signal changes in tissues due to water proton
motion varies based upon degree of cell membrane integrity
(7,8).
The intact membranes of viable tumor cells restrict water
diffusion, whereas necrotic tumor cells with disrupted cell
membranes exhibit increased water diffusion. Previous preclin-
ical and clinical studies have shown that tumor necrosis is
associated with an increase in ADC value, thereby allowing
differentiation between viable and necrotic portions of tumor
(7).
With advances in hardware and coil systems, DWI can now
be applied to liver imaging with improved image quality. DW
MR imaging enables qualitative and quantitative assessment
of tissue diffusivity (by apparent diffusion coefficient) without
the use of gadolinium chelates, which makes it a highly attrac-
tive technique, particularly in patients with severe renal dys-
function (9).
2. Aim of the work
The aim of the current work was directed to study the role of
diffusion weighted magnetic resonance imaging in the assess-
ment of hepatocellular carcinoma after chemoembolization.
3. Patients and methods
Current prospective study included 20 patients diagnosed as
H.C.C. who further underwent trans-arterial chemoemboliza-
tion. All the studied patients subjected to radiological assess-
ment through initial US followed by triphasic MDCT (16
slices) and baseline then follow-up hepatic MRI including
DWI. The medical ethics were considered and patients’ agree-
ment was obtained including informed consent that was
enrolled prior to the study.
Inclusion criteria comprised unresectable tumor, patent
portal vein based on Doppler, no ascites, satisfactory liver
function and no major contraindications to angiography (Nor-
mal coagulation and renal function), whereas exclusion criteria
included clinically apparent jaundice, hepatic encephalopathy,occluded PV, extra-hepatic tumors and non-correctable
coagulopathy.
Unenhanced CT is obtained following conventional TACE
to reveal lipiodol distribution and assess adequate tumor tar-
geting. It is sometimes difficult to detect viable tissue, because
beam hardening artifacts produced by iodized oil can impair
evaluation of arterial enhancement.
MRI for the liver was performed using 1.5-T MRI scanner
(Philips Intera) equipped with phased-array torso surface coil.
The baseline study was obtained before chemoembolization
procedure and included axial T2 weighted and DWI. The
follow-up MRI study was obtained 21 days after chemoem-
bolization and included pre-contrast axial T1 in-phase/out-
phase imaging, T2 weighted, DWI and dynamic contrast study.
T2 weighted images were obtained by T2 fast spin-echo
sequence (repetition timemsec/echo timemsec; 508/100, matrix;
272  237, field of view; 380 mm, section thickness; 10 mm, and
flip angle 90). DWI was obtained by applying three different b
values (0, 300, and 600 s/mm2). The parameters of diffusion
sequence are as follows: repetition time/echo time; 1.2 s/61 ms,
matrix; 124  124, field of view; 369 mm, section thickness;
10 mm, flip angle; 90 and Number of averages; 4.
DCEMRI study was performed after bolus injection of
0.1 mmol/kg body weight of Gd-DTPA. Contrast and saline
injection was performed manually. DCE using T1 THRIVE
(High Resolution Isotropic Volume Examination) technique
was performed in triphasic way; A dynamic series consisted
of one pre-contrast series followed by four successive postcon-
trast series including early arterial, late arterial, and portal
phases imaging with 18–21 s intervals followed by 5-min
delayed phase imaging. Imaging done at end of expiration to
limit the risk of image distortion.3.1. Image analysis
(a) Conventional image analysis: lesions assessed regarding
size and T2 signal characteristics.
(b) Dynamic image analysis: Arterial hyper-vascularity was
regarded as suggestive findings of viable HCC. Mean-
while benign conditions were considered in progressive
persistent enhancement. In some lesions with sponta-
neous T1 hyper intensity, inclusion of subtraction
images was done using a commercially windows work-
station (PHILIPS).
(c) DWI analysis: Signal intensity on DWI with ADC val-
ues was evaluated side to side using windows worksta-
tion. Pattern of diffusion restriction was classified into
heterogeneous or nodular and rim. Benign conditions
were considered when lost signal on diffusion images
(no restriction) or mild sustained hyperintensity with
bright ADC map (shine through effect).
(d) ADC measurement: Pixel-based ADC maps were gener-
ated on the workstation using the three b values (0, 300,
and 600 s/mm2). Normal liver parenchyma was evalu-
ated with randomly drawn region of interest from differ-
ent slices. Artifacts caused by physical limitations and
image distortions were considered. ADC measurement
in heterogeneous lesions with different signals on DWI
was evaluated by placing ROI on corresponding ADC
map at the most restricted solid region where ADC
value is considered to be the lowest in the entire tumor.
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Statistical analysis was performed with web based calculator.
Mean, minimum, and maximum ADC values of the lesions
were evaluated by Wilcoxon signed-rank test. Mean ADC val-
ues of the liver parenchyma were also compared by Wilcoxon
signed-rank test. Differences were considered significant when
P values were less than 0.05.
4. Results
The examined group included eighteen males and two females
with 9:1 ratio. Their ages ranged between forty-two years and
sixty-nine years and mean age was fifty-six years. The peak age
was targeting the sixth and seventh decades.
According to tumor burden, patients were classified accord-
ing to Child classification as follows: 12 patients (60%) with
Child A classification and 8 patients with Child B classification
(40% of cases). Five patients underwent first time TACE while
others received previous loco regional by either TACE or RFA
or combination. Conventional TACE procedure was done in
seventeen patients and beads thereby were used in three patients
in viewofmultiplicity of lesions. The procedureswere performed
successfully in all patients without 24 h major complication.
Table 1 represents the distribution of lesions according to
baseline lesion characteristics including T2 WI baseline signals,
size of the lesions, growth pattern and internal structure.Table 1 Distribution of lesions according to baseline lesion
characteristics.
Character Parameter Frequency Percentage
Size 3–5 cm 8 40
5–8 cm 12 60
T2 Signal Hyper-intense 19 95
iso-intense 1 5
Pattern Nodular 19 95
Infiltrative 1 5
Internal
structure
hemorrhage/fatty
metamorphosis/necrosis
17 85
Homogenous 3 15
Fig. 1 Graph showing liver and tuDiffusion and ADC map analysis before TACE showed sig-
nificantly lower ADC value of the cellular parts in the lesion
than normal appearing liver parenchyma. Mean ADC value in
lowest signal intensity areas before TACE was 1.25 mm2/s
(range 0.75–1.3 mm2/s) while the mean ADC value of the liver
was 1.69 mm2/s (range 1.11–1.8 mm2/sec). Fig. 1 represents
the graph that demonstrates liver and tumorADC values before
TACE.
After TACE the change in tumor size on the T2-weighted
images was not statistically significant ‘‘P value 0.4. The nor-
mal appearing liver parenchyma also showed no significant
changes before and after TACE.
Fifteen out of twenty patients ‘‘75% of the study group”
showed partial response and residual viable tumor tissue was
defined by arterial enhancement (Cases 1 and 2). The diffusion
imaging showed diffusion restriction ’’sustained hyper-
intensity with high b value and low ADC value on ADC
map’’ in thirteen patients (65% of cases). The pattern of diffu-
sion restriction was focal nodular and heterogeneous. Two
patients with lesions in the liver dome showed residual tumor
and were not detected by diffusion imaging.
The necrosis induced after TACE was noted on dynamic
study as non-enhancing portions showed bright signal on the
diffusion images with high ADC value ‘‘mean 1.85 mm2/sec’’
(Case 3).
Table 2 represents correlation between tumor and Liver
ADCs and size before and after TACE. Fig. 2 shows changes
of ADC values of the hepatic lesions after TACE. Fig. 3 shows
comparison between the changes in ADC values of the lesions
measured before and after TACE.
False positive results with diffusion restriction were noted
in two cases (10%) while it shows no enhancement after
dynamic contrast study excluding no residual active tumor tis-
sue (Case 4).
Five patients ’’25% of the study group ’’ showed complete
response defined by disappearance of arterial enhancement in
the target lesions and DWI showed no nodular or heteroge-
neous diffusion restriction in four lesions. One lesion showed
heterogeneous diffusion restriction with no enhancement in
the dynamic study. The complete response lesions showed
delayed persistent peripheral enhancement in all five lesions
with corresponding thin rim of sustained peripheral hyper-
intensity and restriction (Case 5).mor ADC values before TACE.
Fig. 2 Graph demonstrating the linear changes of ADC values between pre and post TACE procedure in examined patients.
Fig. 3 Graph demonstrating, for every individual patient, the differences between the average ADC values before TACE procedure
(blotted as blue line) and those values after TACE procedure (blotted as red line). Notice elevated ADC value in the follow up after TACE
in all patients with variable degrees.
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responding lesions and pretreatment ADC values were not
significant (P. 84). Statistical analysis shows that diffusion
imaging had sensitivity of 86.67%, specificity of 80%, positive
predictive value of 92.86% and negative predictive value of
66.67% to arterial phase enhancement in the dynamic MRI.5. DISCUSSION
Change in tumor size on cross-sectional imaging is the gold
standard for noninvasive assessment according to Response
Evaluation Criteria in Solid Tumors (RECIST) (6).
However, results from a number of previous clinical studies
in HCC have demonstrated that RECIST criteria could not
apply adequately for interventional therapies (10).
Discrepancy between the reduction in tumor size seen on
imaging and the degree of necrosis at histopathology may beexplained by the delayed resorption of the necrotic material
due to the occlusion of the feeding artery and hepatic sinu-
soids. As acknowledged in the original RECIST publication,
assessments based solely on changes in tumor size could be
misleading (1).
In recent study by Kamel et al. performed at 2009, a series
of MRI performed before TACE, 24 h and 1, 2, 3, and 4 weeks
after therapy had been demonstrated that mean tumor size was
unchanged up to 4 weeks after TACE (11).
In the present work, we did once follow-up examination
obtained three weeks after TACE and showed no significant
changes regarding the size of the lesion which is consistent with
Kamel et al. study.
European association for the study of liver (EASL) and
American association for the study of liver diseases (AASLD)
adopted a modification of the RECIST criteria in recent guide-
lines, in which evaluation of the treatment response should
take into account the induction of intra-tumoral necrotic areas
(a)
(c)
(b)
(d)
(e)
Case 1 Male patient 50 years old underwent second time TACE. (a) T2-weighted images after TACE with well-defined right hepatic lobe
lesion showing mild internal heterogeneity. (b and c) DWI and ADC map at b value 600 mm2/sec. Note peripheral nodular restriction
interpreted as neoplastic residual tissue (star). (d and e) DCE MRI showing nodular arterial enhancement and early washout denoting
residual tumor tissue.
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tion in tumor size. Thus the diameter of the target lesions with
viable tumor should guide all measurements (1).
The study done by Kamel et al. (11) demonstrated poor
correlation between lipiodol deposition and tumor enhance-
ment. So, main value of CT is to document the technical suc-
cess of the procedure. Kloeckner et al. (12), stated that MRI
was found to be superior to CT for detection of viable tumor
residuals after lipiodol based TACE, since Iodized oil does not
affect MRI signals.
Signal changes on conventional (T1 and T2) MR imaging
are non-specific and do not correlate with tumor necrosis. It
was reported that T2 hyper-intensity not only represents resid-
ual tumor but could also represent hemorrhage, liquefactive
necrosis, or inflammatory infiltrate. So, it was difficult to assess
the viable HCC tumors after TACE by conventional spin echo
imaging (13).
Current study resultsmatchedwith thementioned ones as T2
signal characteristic showed no significant changes in seventeen
patients. Three patients however showed difference in the T2
appearance manifested by variable degrees of increased signal,so we found that assessment of HCC necrosis after TACE based
on pre-contrast sequences considered a deficient issue.
Use of DWI to probe tumor response is promising, as it
characterizes highly cellular tumor regions versus necrotic
regions as viable tumor cells with intact membranes causing
restricted diffusion whereas necrotic tumors with disrupted cell
membrane have increased water diffusion (14).
DWI offers the advantage of earlier signals of treatment
response, even prior to obvious anatomic changes. In addition,
ADC values add a quantifiable measure of tumor cell death by
directly reporting the state of water diffusion within the tumor,
which is especially valuable because of the wide spectrum of
histopathologic findings after TACE, ranging from total via-
bility to complete necrosis. Successful tumor treatment after
TACE results in diminished blood supply with subsequent
diminished tissue fluid (13).
Several Preclinical animal studies were conducted on ani-
mal models (Geschwind et al. and Yuan et al.) that showed
that following minimally invasive therapies, an increase in
the ADC value may be observed in those responding to treat-
ment (15,16).
Case 2 Male patient 56 years old underwent first time TACE. (A and B) T1 in-phase and out-phase showing no signal drop in out-phase
image. (C and D) DWI and ADC map showing central necrosis and peripheral restriction. (E and F) DCE MRI arterial phase and
subtraction image showing central non-enhancing necrosis.
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studied initially by Kamel et al in 2003 (11). They studied
patients with HCC who underwent chemoembolization as a
bridge for transplantation and found direct correlation
between increasing ADC and increasing necrosis within the
explanted surgical specimen.
They also found that diffusion imaging can quantify necro-
sis after TACE to a greater degree than can gadolinium-
enhanced MRI. However their study had limitations as it
included only a small number of patients, and did not assess
image subtraction and the details of acquisition and processing
of the histopathologic specimens were not reported (11,17).
Another study by Mannelli et al., with larger number of
patients demonstrated that DCE MRI with subtraction tech-
nique had more significant correlation than diffusion imaging
with the histopathologic correlation in the evaluation of necro-
sis of HCC after TACE whereas there was no difference
between the two methods in diagnosis of complete tumor
necrosis (18).
In the study in hand, although histopathologic analysis of
the tumor remains the only reliable method to determine
necrosis, we could not obtain histologic correlation due toobvious ethical reasons as the patients were not suitable for
lesion resection or liver transplantation.
Both studies by Kamel et al. and Mannelli et al. showed
that DWI can be used to assess necrosis which is concomitant
with our results.
Early response of HCC to TACE by DW and MR Spec-
troscopy was assessed by Chen et al. (20) and Bonekamp
et al. (21). Both demonstrated an increase in ADC values
and decreased choline levels significantly which was useful
for assessing the early therapeutic responses.
In the current study, we confirmed that increased intrale-
sional ADC post-TACE was concomitant with therapy-
induced necrosis; however, technical, time and cost factors pre-
cluded MR spectroscopy and future studies are recommended
to establish choline level changes post-TACE.
Sahin et al. (22) using 3.0-T MR showed that there was
increased ADC value from 1.10 to 1.27  103 mm2/s for the
lesion while those for normal liver and spleen remained
unchanged.
The abovementioned studies obtained ADC values of liver
and tumor with considerable variation. Our explanation this
may be a consequence of differences in parameters of DWI
(a)
(c)
(e)
(b)
(d)
(f)
(g)
Case 3 Female patient 61 years with large hepatic mass. (a) Axial T2-weighted image before TACE shows sizable hyperintense HCC.
(b) Diffusion weighted image ‘‘b value 600 mm2/sec” reflecting high signal intensity with diffusion restriction. (c and d) T2-weighted and
T1-weighted images after TACE shows areas of increased signal intensity (arrow). (e) Corresponding diffusion weighted image ‘‘b value
600 mm2/sec”. (f) Corresponding ADC map and area of high ADC value denoting necrosis (arrow). (g) Arterial phase dynamic MRI with
same region points to non-enhancing area of necrosis (arrow).
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adequate exploitation of ADC changes in monitoring response
after TACE necessitates agreement on the appropriate time
interval, DWI parameters including b value and uniform
ADC measurement methodology in order to establish a
functioning cutoff values.According to current study, the impact of ADC value is
limited as nine lesions exceeded 8 cm making overall tumor
ADC measurement impossible, however the ADC maps can
be used as complementary for DWI to eliminate T2 shine
through and visualize the necrosis. Although the reproducibil-
ity in ADC was reported in some studies as a limiting factor,
Table 2 Tumor and Liver ADC and size before and after
TACE.
Mean SD Range
Tumor ADC pre-TACE
mm2/sec
1.357 0.288 0.75–1.9
Tumor ADC post-TACE
mm2/sec
1.606 0.35 1.15–2.08
P value Less than .001
Liver ADC pre-TACE
mm2/sec
1.696 0.33 1.55–2.1
Liver ADC post-TACE
mm2/sec
1.698 0.33 1.45–2.2
P value 0.3409
Tumor size pre-TACE (cm) 5.4 1.15 3–8
Tumor size post-TACE (cm) 5.2 1.18 3–8
P value 0.418
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appearing liver parenchyma before and after TACE while the
targeted lesions showed significant changes.(a)
(c)
(e)
(
(
Case 4 Male patient 65 years old underwent third time TACE. (a an
heterogeneous HCC with arrow points to anterior cystic portion. (c and
T2 shine through.The posterior portion shows diffusion restriction ‘‘F
enhancement.A study carried out by Yuan et al. (19) investigated the
value of pretreatment ADC and proposed that high pretreat-
ment ADC was predictive of poor response. Their results pro-
duced controversy with the current study. Although the reason
for this is unclear, we performed dynamic scan in all patients
as the response depends on the presence of early enhancement,
which was not clearly described by Yuan study.
In a study by Mannelli et al. (14), they used subtraction
images of dynamic post-TACE MRI to assess the necrosis
and correlated with the pretreatment ADC values. They con-
cluded that pre-TACE ADC can potentially be used as predic-
tor of subsequent response to TACE.
The present study suggests a more clinically significant
value of pretreatment diffusion imaging as it could be useful
in patients with multiple focal lesions where ADC can be road
map for conventional TACE on repeated sessions where visu-
alization of enhancement is difficult so it can direct thereby to
the most active non-necrotic lesion without invasive techniques
or contrast administration. It is interesting to mention that, to
the best of our knowledge, no previous study reports such
issue, however naturally to say further studies are needed to
reach firmer conclusion.b)
d)
(f)
d b) T2 and T1 weighted images after TACE showed segment IV
d) Diffusion image and ADC map. Anterior portion is showing to
alse positive”. (e and f) Early and delayed arterial phases show no
Case 5 Male patient 66 years old undergoing second time TACE. (a) DCE-MRI arterial phase CT before TACE showing partly
enhancing solid portion and partly necrotic posterior component. (b) T2-weighted image confirmed heterogeneous necrotic high signals
component. (c) DWI at different b value 600 with area of sustained high signal. (d) ADC map showing necrosis confirmed residual viable
tissues. (e) DCE MRI arterial phase CT after Conventional TACE showing no residual enhancement. (f and g) DWI and ADC map
reflecting T2 shine through effect and thin peripheral restriction. (h) Arterial dynamic MR with no residual enhancing lesions apart from
persistent capsular rim enhancement.
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depicted on DCE-MRI that may be mistaken for residual
tumor yet it may be attributed to various benign conditions
as reactive edema or reactive granulation tissue due to adjacent
inflammation or other non-tumorous arterioportal shunts
(13,23).Yu et al. (23) measured the ADC value to differentiate
between the marginal recurrences of HCC from perilesional
benign conditions and they found that the ADC values varied
widely for the non-tumorous lesions and grossly overlapped
with the viable tumor portion making it impossible to deter-
mine any cutoff points.
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residual HCC but increased false positives, that decreased
specificity, will compromise the increased sensitivity gained
by DWI and so decreased overall diagnostic accuracy. They
referred the increase in false positive findings to perilesional
parenchymal insults that showed hyperintensity with increased
b factors and explained that hyper-cellularity within fibrotic
content in inflammatory granulation tissue could cause
restricted diffusion (23).
Our results are concordance with Yu et al. as there was no
significant difference between the ADC values of perilesional
benign looking restriction and residual tumor. The discrimina-
tion, based on DWI, between thin rim hyperintensity and focal
nodular hyperintensity may have decreased the false positive
results and increased the specificity and sensitivity of diffusion
imaging in our study.
In a study performed by Goshima et al., where DWI was
compared with dynamic MR study, they found that DWI
was not a reliable predictor of local HCC recurrence after
TACE as compared with gadolinium enhanced MR imaging
(24).
In our study, we did not aim to make a comparative study;
we used dynamic MR as a reference. Among our study group
we found one lesion with false positive result, that showed dif-
fusion restriction and no arterial enhancement noted.
In the studies of Holtas et al. (25), sterile liquefactive necro-
sis and intra-cavitary micro-hemorrhage are accepted causes of
hyperintensity in DW MR images of malignant lesions.
False positive finding in our study is likely originating from
intralesional hemorrhage that caused diffusion restriction.
We found that DW MRI had some advantages to DCE
MRI. First, contrast administration, with its known hazards,
was not required, so examination is obtained in a relatively
short time. Second, the technique is easy to be repeated, allow-
ing close follow-up during and after tumor treatment. Third,
image post-processing is less time-consuming compared to
DCE MR imaging. At last, Diffusion-weighted MR imaging
allows easy evaluation of the entire tumor.
This study had several limitations. First, technical difficul-
ties of DWI such as relatively poor signal-to-noise ratio and
partial loss in spatial resolution were caused by increased sen-
sitivity to pulsatile and magnetic susceptibility artifacts.
Lesions close to the diaphragm posed a challenge to DW-
MRI evaluation, as they are more sensitive to motion, suscep-
tibility artifacts, as well as artifacts arising from the heart. We
had two sub-diaphragmatic H.C.C. cases that were excluded
because of low image quality.
Although we placed the smallest ROI possible in the viable
parts of the lesions on the ADC map and made multiple mea-
surements, partial volume effects and uncontrollable image
noise caused unavoidable errors.Second, the sample group
was small with possible selection bias. Third regarding
follow-up data on patient outcomes were not available because
of lack of adequate registration systems and poor patient com-
pliance. Last, we did not assess DWI as a standalone sequence;
instead, DCEMRI was used as guidance to define necrosis and
residual tumor, and this decision may have introduced bias. It
would be interesting to perform future studies comparing DWI
with contrast-enhanced imaging in a more independent
manner.
Studies exploring the potential for using DW-MRI for the
early detection of therapeutic-induced changes in tumors areongoing. Future studies with high magnetic gradient systems
with new technical developments are needed to improve the
image quality and sensitivity of DWI.
6. Conclusion
DWI is a promising technique that proved useful in evaluating
HCC depending on its capability of microscopic tissue charac-
terization. It facilitates distinction between viable and necrotic
tumor areas and helps the diagnosis of residual tumor. Poten-
tial effect of treatment can be detected as an increase in the dif-
fusion coefficient.
In the follow-up after TACE, changes in lesion size alone
could not be used as markers of response and recent guidelines
take into consideration the residual viable tumor. So we rec-
ommend that optimal follow-up after TACE therapy should
include DWI and contrast-enhanced MRI.
DW images are rather difficult to interpret since it is very
sensitive to artifacts especially in the lesions near the dome
of the diaphragm, and also standardizing liver diffusion
protocols must be pursued in order to provide reproducible
parametric quantification.
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